Company research
HeartSciences Inc.
CIK 1468492Updated Nov 14, 2026
Name history
Heart Test Laboratories, Inc. · through Oct 18, 2024
HSCS price & chart
Loading TradingView…
NASDAQ:HSCS on TradingView ↗About the company
HeartSciences is a healthcare information technology company advancing the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™ Platform is a cloud-native, vendor- and device-agnostic ECG management system designed to modernize ECG workflows and improve clinical efficiency and decision-making. The platform’s AI-ECG marketplace is designed to deliver AI-ECG algorithms into clinical workflows across a health system’s existing ECG equipment.
In the news
These Emerging Companies Are Racing Toward Major Catalysts ↗
Recent filings
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 7,554,503Source | 5,703,855Source | 10,800,704Source | 7,777,241Source | 2,368,378Source | 3,737,092Source | — | 8,191,390Source | 5,262,673Source | 4,222,909Source | 9,503,113Source | 3,287,233Source |
| Property, Plant and Equipment, NetUSD | 46,070Source | 71,062Source | 58,393Source | 77,069Source | 53,316Source | 32,980Source | — | 86,127Source | 39,312Source | 63,549Source | 97,991Source | 61,428Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,397,035Source | 2,596,522Source | 7,076,497Source | 4,052,120Source | 100,144Source | 29,906Source | — | 4,339,778Source | 1,656,814Source | 1,098,098Source | 5,807,648Source | 1,660,467Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | — | 14,700Source | — | 3,900Source | — | — | — | 0Source | 4,350Source | — | — |
| Inventory, NetUSD | 657,285Source | 652,147Source | 670,278Source | 652,907Source | 674,839Source | 402,989Source | — | 643,039Source | 655,629Source | 650,267Source | 629,179Source | 676,359Source |
| Assets, CurrentUSD | 5,098,824Source | 3,628,954Source | 8,690,750Source | 5,689,074Source | 1,812,231Source | 811,768Source | — | 6,074,655Source | 2,582,928Source | 2,171,457Source | 7,353,893Source | 2,696,581Source |
| Operating Lease, Right-of-Use AssetUSD | 295,311Source | 395,374Source | 482,743Source | 418,334Source | 502,831Source | 239,871Source | — | 440,529Source | 268,067Source | 371,626Source | 461,983Source | 529,224Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,902,380Source | 3,917,166Source | 2,166,868Source | 3,760,520Source | 4,018,060Source | 5,770,237Source | — | 2,257,432Source | 5,036,613Source | 4,017,738Source | 2,185,812Source | 3,056,676Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | — | — | 381Source |
| Common Stock, Value, IssuedUSD | 3,184Source | 1,032Source | 63,611Source | 948Source | 11,213Source | 3,904Source | — | 907Source | 3,188Source | 1,119Source | 677Source | 10,118Source |
| Additional Paid in CapitalUSD | 85,166,628Source | 75,818,582Source | 74,086,087Source | 75,512,406Source | 62,211,156Source | 86,403,999Source | — | 75,346,766Source | 85,491,469Source | 76,331,307Source | 74,678,650Source | 60,977,256Source |
| Retained Earnings (Accumulated Deficit)USD | -82,518,606Source | -74,033,305Source | -65,516,242Source | -71,497,013Source | -63,872,431Source | -88,441,854Source | — | -69,414,095Source | -85,269,510Source | -76,127,635Source | -67,362,406Source | -60,757,198Source |
| Stockholders' Equity Attributable to ParentUSD | 2,652,123Source | 1,786,689Source | 8,633,836Source | 4,016,721Source | -1,649,682Source | -2,033,145Source | 3,141,111Source | 5,933,957Source | 226,060Source | 205,171Source | 7,317,301Source | 230,557Source |
| Liabilities and EquityUSD | 7,554,503Source | 5,703,855Source | 10,800,704Source | 7,777,241Source | 2,368,378Source | 3,737,092Source | — | 8,191,390Source | 5,262,673Source | 4,222,909Source | 9,503,113Source | 3,287,233Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,268,899Source | 3,571,322Source | 1,706,009Source | 3,302,706Source | 3,531,175Source | 5,632,971Source | — | 1,351,689Source | 4,861,112Source | 3,703,211Source | 1,751,767Source | 1,832,891Source |
| Operating Lease, Liability, CurrentUSD | 133,927Source | 115,015Source | 98,319Source | 110,645Source | 94,463Source | 144,304Source | — | 106,402Source | 139,026Source | 119,518Source | 102,293Source | 29,535Source |
| Accounts Payable, CurrentUSD | 410,727Source | 405,076Source | 415,076Source | 276,848Source | 1,088,297Source | 1,022,767Source | — | 396,506Source | 318,327Source | 318,661Source | 448,183Source | 631,369Source |
| Operating Lease, Liability, NoncurrentUSD | 211,917Source | 345,844Source | 460,859Source | 376,241Source | 486,885Source | 137,266Source | — | 405,743Source | 175,501Source | 314,527Source | 434,045Source | 536,335Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 315,890Source | 584,427Source | 369,673Source | 772,670Source | — | — | 331,098Source | — | 506,307Source | 398,331Source | 623,391Source |
| Intangible Assets, Net (Excluding Goodwill) | —Source | — | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | 738,889Source | 174,558Source | 54,554Source | 1,312,383Source | 249,884Source | 405,025Source | 248,308Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | 0Source | -4,350Source | — | -4,350Source | 4,350Source | — | -2,321Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | -760Source | -760Source | 13,860Source | 5,362Source | 21,088Source | -47,180Source | 2,220Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | 704,440Source | -35,436Source | -51,677Source | -334Source | -129,522Source | -183,186Source | 37,824Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | -1,318,859Source | -1,953,367Source | -2,018,720Source | -7,426,707Source | -7,412,994Source | -6,070,185Source | -5,773,577Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | -280,107Source | -814Source | -833Source | -44,452Source | -30,188Source | -125,271Source | -18,308Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 3,554Source | 3,157Source | 64,455Source | 18,308Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | -27,942Source | 3,648,314Source | 551,683Source | 8,029,875Source | 2,733,632Source | 10,342,637Source | 6,534,092Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | -1,626,908Source | 1,694,133Source | -1,467,870Source | 558,716Source | -4,709,550Source | 4,147,181Source | 742,207Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 2,596,522Source | 4,052,120Source | — | — | 4,339,778Source | — | 1,098,098Source | 5,807,648Source | 1,660,467Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | 100,833Source | 109,950Source | — | 495,950Source | 285,870Source | 103,595Source | 61,381Source |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | 0Source | — | — | 0Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | 6,332Source | 7,111Source | 11,864Source | 27,791Source | 37,599Source | 27,892Source | 26,915Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 61,509Source | 179,477Source | 117,598Source | 235,261Source | 183,688Source | 22,526Source | 753,041Source | 500,453Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,985,208Source | -2,536,292Source | -2,082,918Source | -3,172,344Source | -2,054,994Source | -2,051,689Source | -9,141,875Source | -8,765,229Source | -6,605,208Source | -6,354,290Source |
| Nonoperating Income (Expense)USD | — | — | -56,268Source | -164,820Source | -97,885Source | -233,254Source | -180,875Source | 23,978Source | -729,008Source | -412,658Source | -299,438Source | -241,326Source |
| Operating ExpensesUSD | — | — | 1,928,940Source | 2,371,472Source | 1,985,033Source | 2,940,430Source | 1,875,259Source | 2,075,667Source | 8,415,418Source | 8,355,041Source | 6,318,289Source | 6,115,318Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | 35,000Source | — | — | 200,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 5,241Source | 14,657Source | — | 2,007Source | 2,813Source | — | 24,033Source | — | — | — |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | 0Source | — | 334,249Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | 10,233Source | 0Source | — | 172,839Source | — | — | 5,194,740Source |
| Inventory Write-down | — | — | — | — | — | —Source | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | — | 2,100Source | 1,900Source | — | 4,319Source | 4,350Source | 18,600Source | 5,150Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | — | —Source | —Source | — | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 1,290,365Source | 1,338,354Source | 786,068Source | 2,033,801Source | 878,053Source | 850,736Source | 5,576,406Source | 3,968,936Source | 3,439,735Source | 3,654,450Source |
| Operating Income (Loss)USD | — | — | -1,928,940Source | -2,371,472Source | -1,985,033Source | -2,939,090Source | -1,874,119Source | -2,075,667Source | -8,412,867Source | -8,352,571Source | -6,305,770Source | -6,112,964Source |
| Other Nonoperating Income (Expense)USD | — | — | 5,241Source | 14,657Source | — | 2,007Source | 2,813Source | — | 24,033Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,985,208Source | -2,536,292Source | -2,082,918Source | -3,172,344Source | -2,054,994Source | -2,051,689Source | -9,141,875Source | -8,765,229Source | -6,605,208Source | -6,354,290Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.63Source | -2.57Source | -2.27Source | -0.86Source | -1.58Source | -2.64Source | -3.48Source | -9.34Source | -19Source | -0.8Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | -2.57Source | -2.27Source | — | — | -2.64Source | — | -9.34Source | -19Source | -0.8Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 3,162,257Source | 986,057Source | 917,445Source | 3,668,945Source | 1,303,532Source | 777,746Source | 2,625,421Source | 938,257Source | 352,520Source | 7,950,550Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 986,057Source | 917,445Source | — | — | 777,746Source | — | 938,257Source | 352,520Source | 7,950,550Source |
| Interest Expense (non-operating)USD | — | — | 61,509Source | 179,477Source | 117,598Source | 235,261Source | 183,688Source | 22,526Source | 753,041Source | 500,453Source | — | — |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | 0Source | — | — | 0Source | — | — | — |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | 0Source | — | — | 0Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Gross ProfitUSD | — | — | 0Source | 0Source | — | 1,340Source | 1,140Source | — | 2,551Source | 2,470Source | 12,519Source | 2,354Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 354,080Source | 243,174Source |
| Nonoperating Income (Expense)USD | — | — | -56,268Source | -164,820Source | -97,885Source | -233,254Source | -180,875Source | 23,978Source | -729,008Source | -412,658Source | -299,438Source | -241,326Source |
| Operating ExpensesUSD | — | — | 1,928,940Source | 2,371,472Source | 1,985,033Source | 2,940,430Source | 1,875,259Source | 2,075,667Source | 8,415,418Source | 8,355,041Source | 6,318,289Source | 6,115,318Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | 35,000Source | — | — | 200,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 638,575Source | 1,033,118Source | 1,198,965Source | 906,629Source | 997,206Source | 1,224,931Source | 2,839,012Source | 4,386,105Source | 2,878,554Source | 2,460,868Source |
Offerings
Registration 333-299147
Filing attachments
ea031187501ex99-1.htm · DEFA14A · 2026-11-13
Exhibit 99.1 FORTITUDE’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes thereto and the other financial information included elsewhere in HeartSciences Inc.’s Current Report on Form 8-K (the “Form 8-K”) to which this Management’s Discussion and Analysis of Financial Condition an…
Read attachment ↗ea031187501ex99-2.htm · DEFA14A · 2026-11-13
Exhibit 99.2 Fortitude Mining Holdings, Inc. and Subsidiaries Table of Contents Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025 F-2 Condensed Consolidated Statements of Operations for the Nine Months Ended September 30, 2026 and 2025 (unaudited) F-3 Condensed Consolidated Statements of Changes in Stockholder’s / Member’s Equity for the Nine Months E…
Read attachment ↗ea031187501ex99-1.htm · 8-K/A · 2026-11-13
Exhibit 99.1 FORTITUDE’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes thereto and the other financial information included elsewhere in HeartSciences Inc.’s Current Report on Form 8-K (the “Form 8-K”) to which this Management’s Discussion and Analysis of Financial Condition an…
Read attachment ↗ea031187501ex99-2.htm · 8-K/A · 2026-11-13
Exhibit 99.2 Fortitude Mining Holdings, Inc. and Subsidiaries Table of Contents Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025 F-2 Condensed Consolidated Statements of Operations for the Nine Months Ended September 30, 2026 and 2025 (unaudited) F-3 Condensed Consolidated Statements of Changes in Stockholder’s / Member’s Equity for the Nine Months E…
Read attachment ↗ea030780201ex99-1.htm · DEFA14A · 2026-10-06
Exhibit 99.1 HeartSciences Receives FDA 510(k) Clearance for its MyoVista ® wav ECG TM Device Southlake, TX, October 6, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted 510(k) clearance (K260005) f…
Read attachment ↗ea030780201ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 HeartSciences Receives FDA 510(k) Clearance for its MyoVista ® wav ECG TM Device Southlake, TX, October 6, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted 510(k) clearance (K260005) f…
Read attachment ↗